123 results
424B3
CYDY
CytoDyn Inc.
16 Apr 24
Prospectus supplement
5:16pm
in the clinical development of leronlimab and is exploring potential business opportunities to continue the investigation of leronlimab for solid tumors
424B3
CYDY
CytoDyn Inc.
16 Apr 24
Prospectus supplement
5:15pm
in the clinical development of leronlimab and is exploring potential business opportunities to continue the investigation of leronlimab for solid tumors
424B3
lapx9vh53i pjfh
19 Jan 24
Prospectus supplement
5:15pm
424B3
2md20gij4 rqil
24 Oct 23
Prospectus supplement
6:01am
424B3
vifhxxhkksacn k6i
10 Oct 23
Prospectus supplement
6:02pm
POS AM
u4p hxxm97
2 Oct 23
Prospectus update (post-effective amendment)
5:15pm
424B3
2prr0u53xfwoapn8k0
11 Jul 23
Prospectus supplement
5:28pm
8-K
EX-99.1
4mt2uu jy
28 Oct 22
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
5:15pm